domperidone has been researched along with Cardiac Conduction Defect in 4 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The first author performed EMBASE, PubMed and Scopus searches to identify human studies assessing the association between current domperidone exposure and cardiac arrhythmia or sudden death." | 8.93 | Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis. ( Holcombe, A; Leelakanok, N; Schweizer, ML, 2016) |
| "The first author performed EMBASE, PubMed and Scopus searches to identify human studies assessing the association between current domperidone exposure and cardiac arrhythmia or sudden death." | 4.93 | Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis. ( Holcombe, A; Leelakanok, N; Schweizer, ML, 2016) |
| "A search of two bibliographic databases, the European Medicines Agency (EMA) website, Micromedex, Lexicomp and reference texts was undertaken for domperidone related reports of QT prolongation, cardiac arrhythmias and/or SCD." | 4.91 | Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations. ( Buffery, PJ; Strother, RM, 2015) |
| "Risk-minimization measures (RMM), including label revisions were implemented in Europe for domperidone because of evidence of increased incidence of cardiac arrhythmia and sudden cardiac death." | 3.91 | Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe. ( Fife, D; Hu, P; Kaplan, S; Oliveria, SA; Phillips, S; Richarz, U; Waller, J, 2019) |
| "Observational retrospective studies have linked domperidone and prolonged QT interval, ventricular arrhythmias and risk of sudden death." | 3.85 | [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database]. ( Auffret, M; Béné, J; Gautier, S; Rochoy, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fife, D | 1 |
| Waller, J | 1 |
| Kaplan, S | 1 |
| Hu, P | 1 |
| Phillips, S | 1 |
| Oliveria, SA | 1 |
| Richarz, U | 1 |
| Buffery, PJ | 1 |
| Strother, RM | 1 |
| Leelakanok, N | 1 |
| Holcombe, A | 1 |
| Schweizer, ML | 1 |
| Rochoy, M | 1 |
| Auffret, M | 1 |
| Béné, J | 1 |
| Gautier, S | 1 |
2 reviews available for domperidone and Cardiac Conduction Defect
| Article | Year |
|---|---|
Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
Topics: Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Death, Sudde | 2015 |
Domperidone and Risk of Ventricular Arrhythmia and Cardiac Death: A Systematic Review and Meta-analysis.
Topics: Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Case-Control | 2016 |
2 other studies available for domperidone and Cardiac Conduction Defect
| Article | Year |
|---|---|
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe.
Topics: Adult; Antiemetics; Arrhythmias, Cardiac; Cardiac Conduction System Disease; Cross-Sectional Studies | 2019 |
[Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Car | 2017 |